Cognition Therapeutics (CGTX) Convertible Debt (2020)
Cognition Therapeutics (CGTX) reported Convertible Debt of $12.4 million for Q4 2020.
Cognition Therapeutics (CGTX) has 1 years of Convertible Debt data on file, last reported at $12.4 million in Q4 2020.
- Quarterly Convertible Debt changed N/A year-over-year to $12.4 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $12.4 million (changed N/A YoY) and the FY2020 annual result came in at $12.4 million, changed N/A from the prior year.
- Convertible Debt held at $12.4 million in Q4 2020 per CGTX's latest filing.
- Across five years, Convertible Debt topped out at $12.4 million in Q4 2020 and bottomed at $12.4 million in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn |
| 10 | Cognition Therapeutics | 648,270.00 | 648,270.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 12.41 Mn |